Janux Therapeutics (JANX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Janux Therapeutics (JANX) is Neutral.

The composite score behind that read is -0.18, weighing +0.08 of bullish evidence against -0.26 bearish.

Janux Therapeutics last closed at $16.54, -2.30% on the session.

Against the IVW growth benchmark the position is -3.22% over the forecast window.

The read is built from 11 underlying insights — 2 bullish and 9 bearish.

Agreement across those insights is 82%.

12 graded predictions for JANX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Janux Therapeutics in the 31st percentile on return on equity, where 100 is best.

Janux Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $1.04B.

StockMap tracks Janux Therapeutics as the 122nd largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Janux Therapeutics ranks 134th of 344 in the group, against a group median of -0.21.